

AMENDMENTS TO THE CLAIMS

The following is a complete listing of the claims indicating the current status of each claim:

1-27 (Canceled)

Please add the following Claims:

28. (NEW) A pharmaceutical composition, the composition comprising a physiologically effective amount of a mixture of at least one conjugated fatty acid and at least one polyphenol, a pharmaceutically effective carrier and excipients.

29. (NEW) The pharmaceutical composition of claim 28, wherein said conjugated fatty acid includes a trienoic acid.

30. (NEW) The pharmaceutical composition of claim 29, wherein said trienoic acid includes punicic acid.

31. (NEW) The pharmaceutical composition of claim 28, wherein said polyphenol includes ellagic acid.

32. (NEW) The pharmaceutical composition of claim 28, wherein said conjugated fatty acid includes punicic acid and said polyphenol includes ellagic acid.

33. (NEW) The pharmaceutical composition of claim 28, wherein said polyphenol includes at least one member of the group consisting of caffeic acid and luteolin.

34. (NEW) The pharmaceutical composition of claim 31, wherein said conjugated fatty acid includes punicic acid.

35. (NEW) The pharmaceutical composition of claim 28, wherein said conjugated fatty acid is present as punicic acid and comprises 30 to 35 percent of said mixture and said polyphenols include at least one member of the group consisting of luteolin and caffeic acid and comprise the remaining 65 to 70% of said mixture.

36. (NEW) The pharmaceutical composition of claim 33, wherein said luteolin and said caffeic acid each comprise at least 40 % of said polyphenols.

37. (NEW) The pharmaceutical composition of claim 28, wherein said polyphenol includes a phenolic acid.

38. (NEW) The pharmaceutical composition of claim 35, wherein said phenolic acid includes at least one member selected from the group consisting of quinic acid and caffeic acid.

39. (NEW) The pharmaceutical composition of claim 28, wherein said polyphenol includes an ellagi-tannin.

40. (NEW) The pharmaceutical composition of claim 37, wherein said ellagi-tannin includes at least one member selected from the group consisting of ellagic acid and punicalagin.

41. (NEW) The pharmaceutical composition of claim 28, wherein said polyphenol includes a flavonoid (e.g., quercetin, luteolin).

42. (NEW) The pharmaceutical composition of claim 28, wherein said flavonoid includes at least one member selected from the group consisting of quercetin and luteolin.

43. (NEW) The pharmaceutical composition of claim 28, wherein said physiologically effective amount includes dosages in the range of 5 to 25 mg/kg of body weight of a subject treated with the composition.

44. (NEW) The pharmaceutical composition of claim 28, supplied in an orally administrable form.

45. (NEW) A method for management of diabetes mellitus, the method comprising administering a pharmaceutical composition according to claim 28.

46. (NEW) A pharmaceutical composition according to claim 28 supplied as an article of manufacture further comprising packaging material and instructions for use in management of diabetes mellitus.

47. (NEW) A method for management of atherosclerotic disease, the method comprising administering a pharmaceutical composition according to claim 28.

48. (NEW) A pharmaceutical composition according to claim 28 supplied as an article of manufacture further comprising packaging material and instructions for use in management of atherosclerotic disease.

49. (NEW) A method for treatment of a cell proliferation disorder, the method comprising administering a pharmaceutical composition according to claim 28.

50. (NEW) A pharmaceutical composition according to claim 28 supplied as an article of manufacture further comprising packaging material and instructions for use in treatment of a cell proliferation disorder.

51. (NEW) The method of claim 28, wherein said cell proliferation disorder is prostate cancer and practice of the method reduces an invasive capability of said prostate cancer.

52. (NEW) A method for treatment of obesity, the method comprising administering a pharmaceutical composition according to claim 28.

53. (NEW) A pharmaceutical composition according to claim 28 supplied as an article of manufacture further comprising packaging material and instructions for use in treatment of obesity.

54. (NEW) Use of a mixture of at least one conjugated fatty acid and at least one polyphenol in the manufacture or preparation of a medicament.